JP2023022236A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023022236A5 JP2023022236A5 JP2022192727A JP2022192727A JP2023022236A5 JP 2023022236 A5 JP2023022236 A5 JP 2023022236A5 JP 2022192727 A JP2022192727 A JP 2022192727A JP 2022192727 A JP2022192727 A JP 2022192727A JP 2023022236 A5 JP2023022236 A5 JP 2023022236A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- membered ring
- ring containing
- formula
- liver disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052799 carbon Inorganic materials 0.000 claims 19
- 229910052757 nitrogen Inorganic materials 0.000 claims 19
- 229910052760 oxygen Inorganic materials 0.000 claims 16
- 229910052717 sulfur Inorganic materials 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 9
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 8
- 208000019423 liver disease Diseases 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 4
- KPRZOPQOBJRYSW-UHFFFAOYSA-N o-hydroxybenzylamine Natural products NCC1=CC=CC=C1O KPRZOPQOBJRYSW-UHFFFAOYSA-N 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 235000016709 nutrition Nutrition 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024213390A JP2025032245A (ja) | 2016-09-06 | 2024-12-06 | 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）、ｎａｓｈ、ａｌｄまたは肝臓に関する状態の治療、予防または改善のためのガンマ－ケトアルデヒドスカベンジャーの組成物および使用方法 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662383895P | 2016-09-06 | 2016-09-06 | |
| US62/383,895 | 2016-09-06 | ||
| US201662410133P | 2016-10-19 | 2016-10-19 | |
| US62/410,133 | 2016-10-19 | ||
| PCT/US2017/050317 WO2018048932A1 (en) | 2016-09-06 | 2017-09-06 | Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver |
| JP2019512804A JP7189127B2 (ja) | 2016-09-06 | 2017-09-06 | 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）、ｎａｓｈ、ａｌｄまたは肝臓に関する状態の治療、予防または改善のためのガンマ－ケトアルデヒドスカベンジャーの組成物および使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019512804A Division JP7189127B2 (ja) | 2016-09-06 | 2017-09-06 | 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）、ｎａｓｈ、ａｌｄまたは肝臓に関する状態の治療、予防または改善のためのガンマ－ケトアルデヒドスカベンジャーの組成物および使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024213390A Division JP2025032245A (ja) | 2016-09-06 | 2024-12-06 | 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）、ｎａｓｈ、ａｌｄまたは肝臓に関する状態の治療、予防または改善のためのガンマ－ケトアルデヒドスカベンジャーの組成物および使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023022236A JP2023022236A (ja) | 2023-02-14 |
| JP2023022236A5 true JP2023022236A5 (enExample) | 2023-03-16 |
Family
ID=61562136
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019512804A Active JP7189127B2 (ja) | 2016-09-06 | 2017-09-06 | 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）、ｎａｓｈ、ａｌｄまたは肝臓に関する状態の治療、予防または改善のためのガンマ－ケトアルデヒドスカベンジャーの組成物および使用方法 |
| JP2022192727A Pending JP2023022236A (ja) | 2016-09-06 | 2022-12-01 | 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）、ｎａｓｈ、ａｌｄまたは肝臓に関する状態の治療、予防または改善のためのガンマ－ケトアルデヒドスカベンジャーの組成物および使用方法 |
| JP2024213390A Pending JP2025032245A (ja) | 2016-09-06 | 2024-12-06 | 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）、ｎａｓｈ、ａｌｄまたは肝臓に関する状態の治療、予防または改善のためのガンマ－ケトアルデヒドスカベンジャーの組成物および使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019512804A Active JP7189127B2 (ja) | 2016-09-06 | 2017-09-06 | 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）、ｎａｓｈ、ａｌｄまたは肝臓に関する状態の治療、予防または改善のためのガンマ－ケトアルデヒドスカベンジャーの組成物および使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024213390A Pending JP2025032245A (ja) | 2016-09-06 | 2024-12-06 | 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）、ｎａｓｈ、ａｌｄまたは肝臓に関する状態の治療、予防または改善のためのガンマ－ケトアルデヒドスカベンジャーの組成物および使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20180153827A1 (enExample) |
| EP (1) | EP3510014A4 (enExample) |
| JP (3) | JP7189127B2 (enExample) |
| CN (2) | CN110177771B (enExample) |
| AU (1) | AU2017324935B2 (enExample) |
| CA (1) | CA3035897A1 (enExample) |
| MX (1) | MX2019002579A (enExample) |
| WO (1) | WO2018048932A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019022523A2 (pt) | 2017-04-27 | 2020-05-12 | Vanderbilt University | Métodos para tratamento de aterosclerose com sequestrantes de gama-cetoaldeído |
| AU2018330416B2 (en) * | 2017-09-05 | 2024-09-26 | Mti Biotech, Inc. | Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving fibrosis of the liver |
| HUE072226T2 (hu) * | 2019-01-25 | 2025-11-28 | Mti Biotech Inc | Trifenilfoszfóniumhoz kötött szalicilamin származékok |
| CN114344448A (zh) * | 2022-01-20 | 2022-04-15 | 广西医科大学第一附属医院 | Pmx-53多肽在制备治疗非酒精性脂肪性肝炎药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE241982T1 (de) * | 1998-10-22 | 2003-06-15 | Univ South Carolina | Verfahren zur hemmung von diabetischen komplikationen |
| DE60045890D1 (de) * | 1999-04-27 | 2011-06-09 | Mitsubishi Tanabe Pharma Corp | Arzneimittel zur präventiven oder therapeutische Behandlung von Lebererkrankungen |
| CN1628650A (zh) * | 2003-12-19 | 2005-06-22 | 刘力 | 复方二氯醋酸二异丙胺冻干粉针制剂及其制备方法 |
| US8822542B2 (en) * | 2004-10-20 | 2014-09-02 | Vanderbilt University | Isoketal scavengers and mitigation of disorders involving oxidative injury |
| WO2008070778A2 (en) * | 2006-12-06 | 2008-06-12 | Nephrogenex Inc. | Pyridoxamine and low molecular weight heparinoids for diabetic kidney disease |
| US20110117194A1 (en) | 2008-04-29 | 2011-05-19 | Hanall Biopharma Co., Ltd. | Pharmaceutical formulation containing angiotensin-ii receptor blocker |
| EP2731597B1 (en) * | 2011-07-12 | 2023-12-20 | Vanderbilt University | Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers |
| US20150087660A1 (en) * | 2012-05-10 | 2015-03-26 | Mahesh Kandula | Compositions and methods for the treatment of chronic diseases and inflammatory disorders |
| US20150265584A1 (en) | 2014-03-18 | 2015-09-24 | Vanderbilt University | Levuglandin adducts histone h4 in a cyclooxygenase-2-dependent manner, altering its interaction with dna |
| EP3217977A1 (en) | 2014-11-11 | 2017-09-20 | Vanderbilt University | Methods for limiting acute kidney injury |
| WO2017033119A1 (en) * | 2015-08-25 | 2017-03-02 | Rao M Surya | Compositions and methods for the treatment of liver metabolic diseases |
| US20210023032A1 (en) * | 2017-09-05 | 2021-01-28 | Mti Biotech, Inc. | Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver |
| AU2018330416B2 (en) | 2017-09-05 | 2024-09-26 | Mti Biotech, Inc. | Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving fibrosis of the liver |
-
2017
- 2017-09-06 CN CN201780064767.2A patent/CN110177771B/zh active Active
- 2017-09-06 AU AU2017324935A patent/AU2017324935B2/en active Active
- 2017-09-06 WO PCT/US2017/050317 patent/WO2018048932A1/en not_active Ceased
- 2017-09-06 EP EP17849471.2A patent/EP3510014A4/en active Pending
- 2017-09-06 JP JP2019512804A patent/JP7189127B2/ja active Active
- 2017-09-06 CN CN202211453642.8A patent/CN119345198A/zh active Pending
- 2017-09-06 CA CA3035897A patent/CA3035897A1/en active Pending
- 2017-09-06 MX MX2019002579A patent/MX2019002579A/es unknown
- 2017-09-06 US US15/697,193 patent/US20180153827A1/en not_active Abandoned
-
2022
- 2022-12-01 JP JP2022192727A patent/JP2023022236A/ja active Pending
- 2022-12-08 US US18/077,832 patent/US12383515B2/en active Active
-
2024
- 2024-12-06 JP JP2024213390A patent/JP2025032245A/ja active Pending
-
2025
- 2025-08-07 US US19/294,041 patent/US20250360094A1/en active Pending